Open AccessConcise Drug Review: Pazopanib and Axitinib
Author(s) -
Geel Robin M.J.M.,
Beijnen Jos H.,
Schellens Jan H.M.
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2012-0055
Subject(s) - pazopanib , axitinib , medicine , pharmacology , clinical pharmacology , pharmacokinetics , drug , pharmacodynamics , oncology , renal cell carcinoma , sunitinib
Learning Objectives After completing this course, the reader will be able to: Identify the current indications for pazopanib and axitinib. Describe the mechanism of action and the pharmacokinetics of pazopanib and axitinib. Enumerate the clinical benefits of pazopanib and axitinib, and describe the position of these drugs in the treatment paradigm of metastatic renal cell cancer.This article is available for continuing medical education credit at CME.TheOncologist.com Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP‐competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have enlarged the armamentarium for this disease. This concise drug review discusses the clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics, pharmacodynamics, drug resistance, toxicity, and patient instructions and recommendations for supportive care for these two drugs.